Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 18:12:640700.
doi: 10.3389/fphys.2021.640700. eCollection 2021.

Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases

Tingting Li  1 , Chao Yu  1 , Shougang Zhuang  1   2
Affiliations
Review

Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases

Tingting Li et al. Front Physiol. .

Abstract

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme that catalyzes the addition of methyl groups to histone H3 at lysine 27, leading to gene silencing. Mutation or over-expression of EZH2 has been linked to many cancers including renal carcinoma. Recent studies have shown that EZH2 expression and activity are also increased in several animal models of kidney injury, such as acute kidney injury (AKI), renal fibrosis, diabetic nephropathy, lupus nephritis (LN), and renal transplantation rejection. The pharmacological and/or genetic inhibition of EZH2 can alleviate AKI, renal fibrosis, and LN, but potentiate podocyte injury in animal models, suggesting that the functional role of EZH2 varies with renal cell type and disease model. In this article, we summarize the role of EZH2 in the pathology of renal injury and relevant mechanisms and highlight EZH2 as a potential therapeutic target for kidney diseases.

Keywords: acute kidney injury; chronic kidney disease; diabetic nephropathy; enhancer of zeste homolog 2 (EZH2); epigenetic regulation; histone methyltransferase (HMT); renal cell carcinoma; renal fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Alicic R. Z., Rooney M. T., Tuttle K. R. (2017). Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12 2032–2045. 10.2215/cjn.11491116 - DOI - PMC - PubMed
    1. Aloia L., Di Stefano B., Di Croce L. (2013). Polycomb complexes in stem cells and embryonic development. Development 140 2525–2534. 10.1242/dev.091553 - DOI - PubMed
    1. Au C. P., Raynes-Greenow C. H., Turner R. M., Carberry A. E., Jeffery H. (2013). Fetal and maternal factors associated with neonatal adiposity as measured by air displacement plethysmography: a large cross-sectional study. Early Hum. Dev. 89 839–843. 10.1016/j.earlhumdev.2013.07.028 - DOI - PubMed
    1. Ballestar E., Esteller M., Richardson B. C. (2006). The epigenetic face of systemic lupus erythematosus. J. Immunol. 176 7143–7147. 10.4049/jimmunol.176.12.7143 - DOI - PubMed
    1. Bamidele A. O., Svingen P. A., Sagstetter M. R., Sarmento O. F., Gonzalez M., Braga Neto M. B., et al. (2019). Disruption of FOXP3-EZH2 interaction represents a pathobiological mechanism in intestinal inflammation. Cell Mol. Gastroenterol. Hepatol. 7 55–71. 10.1016/j.jcmgh.2018.08.009 - DOI - PMC - PubMed